Abstract
Rapid Achievement of MR4.5 after Switching from Imatinib to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
